B2B, B2G company aims to establish a consulting firm focused on providing expert and advisory services in the fields of biological, veterinary and medical sciences. The main emphasis is on consultation and expertise in the development, research and production in areas of nano-biotechnologies, virology, immunobiology, microbiology, biosecurity, biosafety, bio-risks prevention, infectious diseases, with the goal of supporting innovations and the development of scientific and production potential. The company plans to operate on the international market, attracting leading scientists and specialists. Currently there are 11 high level experts and consultants in the areas from: USA, UK, Germany, Ukraine, etc.

Zinaida Klestova, Prof. Dr., founder

Des Produktes / der Dienstleistung:
High quality expertise and consulting services in the field of pathogen research, prevention of bio-risks, issues related to the development of new biotechnologies, immunobiological drugs, cellular technologies, preparation of project regulatory and legislative bases for new processes, methods and approaches, solving bioethical issues in biological research, and consulting services for B2B and B2G in the countries of the European Union, the United Kingdom, Canada, the USA, South American countries, Africa, the Asian region, the Caucasus, Turkey, Australia, Ukraine.
Der Kundinnen und Kunden: R&D institutions in life sciences, medical sciences, veterinary sciences; small, medium and large biotechnology and pharmaceutical companies; government structures
Der Marktchancen:
In 2023, the global life science consulting services market size reached USD 14.8 billion, and it is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 8.3% from 2023 to 2030. The biotechnology services market size has grown strongly in recent years. It will grow from $ 126.56 billion in 2023 to $ 133.74 billion in 2024 at compound annual grow rate (CAGR) of 5.5%.
Des Finanzierungsplans:
Estimated financial activity for the next 5 years. With the return of the initially deposited peeseed funds, the company is self-sustaining from the fourth year of activity.
Financial data 2024 2025 2026 2027 2028
Sales volume 20,000.00 60,000.00 200,000.00 280,000.00 380,000.00.
Earnings Before Interest and Taxes 20,000.00 60,000.00 71,400.00 104,000.00 156,000.00
Number of employees) 5 5 5 6 7
Capital require-ments 90,000.00 165,397.00 128,600.00 176,000.00 224,000.00
Requested amount of financial support from outside
Der Profitabilität sowie der Nachhaltigkeit der Geschäftsidee.
Profitability: depends on the number of clients. Attracting clients is carried out by three people: sales manager, marketing manager, company owner. Prognostically, the company has the potential to take 10% of the consulting services market in the biotech sector, which is about $ 13.374 billion.
Sustainability of the business idea: The Global Life Science Consulting Services Market is expected to witness a growth rate of 10% in the next five years. Life science consulting assists companies to enhance their management and operations with regards to services such as clinical development services, regulatory services, compliance consulting, and pricing & market access, among others. These life science consulting services help pharma and med-tech firms manage their internal organizational structures more effectively, thereby delivering better outcomes. The life science consulting services market can be analyzed based on industry types, such Pharmaceuticals and Biopharmaceuticals, Medical Devices and Diagnostics, and Biotechnology. Pharmaceuticals and Biopharmaceuticals is the largest end-user segment. This sector's size is attributed to the extensive need for consulting services across various stages of drug development, market access, regulatory affairs, and health economics. The Biotechnology sector is the fastest-growing end-user segment.